With this cohort, we ultimately aim to study the impact of CHEK2 c.1100delC on cancer risk prediction and surveillance, and treatment of breast cancer and prognosis within CHEK2 c.1100delC families. This evidence concerns the gene CHEK2 and breast carcinoma.